NexGel, Inc. develops and commercializes healthcare, beauty and over-the-counter products built around high-water-content hydrogel technology for healthcare and consumer applications.
Company news commonly covers operating and financial results, hydrogel and biomaterial product activity, strategic partnerships, acquisition and licensing activity, financing arrangements, and governance changes. Recent updates also document the launch of BioNX Surgical following a completed license and asset acquisition of commercial-stage regenerative biomaterial products.
NEXGEL (NASDAQ:NXGL) announced the spin-off of select drug delivery assets into a new company, NexGelRx, which will develop prescription drug delivery products using NEXGEL’s hydrogel technology.
Under the agreement NEXGEL will receive a 5% global royalty in perpetuity, retain a 19.99% equity stake in NexGelRx that is non-dilutive for up to $8 million of capital investment, and serve as the exclusive manufacturer of hydrogel for NexGelRx. NexGelRx closed initial outside funding and will focus exclusively on Rx commercialization while NEXGEL remains focused on manufacturing and consumer products.
NEXGEL (NASDAQ: NXGL) reported third quarter 2025 results for the period ended September 30, 2025. Net revenue was $2.93 million, essentially flat year‑over‑year and sequentially. Gross profit was $1.24 million and gross margin improved to 42.4% from 39.3% in Q3 2024. Net loss attributable to NEXGEL stockholders was $0.65 million. EBITDA was ($0.55) million and Adjusted EBITDA was ($0.35) million, with Adjusted EBITDA narrowing sequentially. As of September 30, 2025, cash totaled approximately $938 thousand and restricted cash totaled $920 thousand related to $1 million non‑dilutive capital from STADA. Shares outstanding as of November 11, 2025: 8,143,133.
NEXGEL (NASDAQ:NXGL) will report third quarter 2025 financial results after market close on November 11, 2025. Management will host a conference call the same day at 4:30 P.M. ET to discuss the results and answer questions.
Call details: live dial-in 1-800-579-2543 (U.S. toll free) or 1-785-424-1789 (international); webcast via the company's Events and Presentations page. A replay is available through November 25, 2025 at 1-844-512-2921 (U.S. toll free) or 1-412-317-6671 (international) using code 11160116. An archived webcast will remain available for 90 days.
NEXGEL (NASDAQ: NXGL) announced that CEO Adam Levy will present at the LD Micro Main Event XIX conference in San Diego on October 20, 2025 at 11:30 a.m. PT. The presentation takes place at the Hotel Del Coronado in Track 4 and will be available via webcast.
Investors can access the live webcast at https://ir.nexgel.com/news-events/events-presentations. To request a one-on-one meeting with Mr. Levy during the event, contact KCSA Strategic Communications at Nexgel@KCSA.com.
NEXGEL (NASDAQ: NXGL) reported strong Q2 2025 financial results with revenue reaching $2.88 million, marking a significant 100.3% increase year-over-year. The company achieved substantial margin improvement with gross profit margin expanding to 43.6% from 20.3% in Q2 2024.
Key highlights include a reduced net loss of $0.67 million (vs. $0.89 million in Q2 2024) and improved Adjusted EBITDA of ($0.42) million. Post-quarter, NEXGEL secured a $1 million non-dilutive advance from STADA and raised $1.05 million in additional financing. The company maintains its 2025 guidance of $13 million in revenue and expects to achieve positive EBITDA during the year.
NEXGEL (NASDAQ: NXGL), a provider of ultra-gentle hydrogel products for healthcare and consumer applications, will release its Q2 2025 financial results on August 12, 2025, after market close.
The company will host a conference call at 4:30 P.M. ET on the same day. Investors can join via phone at 1-800-274-8461 (U.S.) or 1-203-518-9814 (International). A replay will be available through August 26, 2025, and the webcast will be archived for 90 days.
NEXGEL (NASDAQ: NXGL), a provider of medical and OTC hydrogel products, has appointed Steve Ciardiello, CPA, to its Board of Directors. As the current Chief Accounting Officer of Shutterstock (NYSE: SSTK), Ciardiello brings over 25 years of senior finance executive experience.
Ciardiello's expertise includes financial leadership, strategic execution, and corporate governance in high-growth public companies. At Shutterstock, he leads a global finance team managing SEC reporting, tax, internal audit, and general accounting. His background includes implementing financial transformation initiatives and over 15 years of Big 4 public accounting experience.
NEXGEL (NASDAQ: NXGL), a provider of medical and OTC hydrogel products, has announced a $950,000 registered direct offering at $2.30 per share, issuing 413,044 shares of common stock. The company is also conducting a concurrent private placement of unregistered warrants to purchase up to 206,522 shares at an exercise price of $4.25 per share.
The warrants will be exercisable immediately upon issuance with a five-year term. This financing, combined with their current cash position and a recent $1 million non-dilutive advance from STADA, aims to strengthen NEXGEL's balance sheet as they prepare for anticipated growth in the second half of the year. Alere Financial Partners, LLC served as the exclusive placement agent for the offering.
NEXGEL (NASDAQ:NXGL), a hydrogel products manufacturer, has expanded its partnership with STADA Arzneimittel AG for the North American market. The collaboration focuses on launching digestive enzyme formulas and solutions for scars and stretch marks.
As part of this strategic expansion, STADA will provide $1 million in non-dilutive capital to support NEXGEL's product launches and marketing initiatives. The partnership aims to bring innovative health solutions to North American consumers, leveraging NEXGEL's expertise in high-water-content hydrogel products and STADA's position as a European consumer health leader.